Emerging Areas in the Treatment of DCIS
DCIS (ductal carcinoma in situ) is a non-invasive breast cancer.
Many issues about how best to treat DCIS are under study, including:
- Ways to predict which cases of DCIS will progress to invasive breast cancer (to target treatment to those who are at higher risk)
- Determining which women may not need radiation therapy after lumpectomy for DCIS
After discussing the benefits and risks with your health care provider, we encourage you to join a clinical trial if there is one right for you.
Susan G. Komen® Breast Cancer Clinical Trial Information Helpline
If you or a loved one needs information or resources about clinical trials, call our Clinical Trial Information Helpline at 1-877 GO KOMEN (1-877- 465- 6636) or email email@example.com.
The Helpline offers breast cancer clinical trial education and support, such as:
BreastCancerTrials.org in collaboration with Susan G. Komen® offers a custom matching service to help find clinical trials that fit your health needs.
Learn more about clinical trials.
Lumpectomy with or without radiation therapy
Radiation therapy after lumpectomy for DCIS decreases the risk of [2-9]:
- DCIS recurrence (a return of DCIS)
- Invasive breast cancer
Since radiation therapy after lumpectomy for DCIS doesn’t improve survival, there are questions about the need for all women to get radiation therapy after lumpectomy for DCIS.
Researchers are studying which women might be able to avoid radiation therapy after lumpectomy for DCIS.
Some women with small, low grade DCIS and clean surgical margins have a low risk of recurrence after lumpectomy. Some of these women may choose to have accelerated partial breast radiation therapy or avoid radiation therapy altogether [2,9-10].
For a summary of research studies on lumpectomy plus radiation therapy as a treatment for DCIS, visit the Breast Cancer Research Studies section.
Oncotype for DCIS
Oncotype DX® is a test that helps predict the chance of metastasis (when cancer spreads to other organs) for some invasive breast cancers. It tests a sample of the tumor (removed during a biopsy or surgery) for a group of 21 genes.
The Oncotype DX test for invasive breast cancer has been modified to help predict the chance DCIS will return as DCIS or invasive breast cancer [17-18].
This test might help identify which cases of DCIS would benefit most from radiation therapy after lumpectomy (and which women might be treated with lumpectomy alone) [17-18].
The Oncotype test for DCIS needs further study and is not part of standard care.
Learn more about Oncotype DX and treatment for invasive breast cancer.
Our commitment to research
At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. Our Research Program is an essential driving force for achieving this mission.
Since our inception in 1982, Komen has provided funding to support research grants that have greatly expanded our knowledge of breast cancer and helped us understand that breast cancer is not just a single disease but many diseases, unique to each individual.
To date, Komen has provided more than $1 billion to researchers in 47 states, the District of Columbia and 24 countries to support research that has resulted in a better understanding of breast cancer; earlier detection; personalized, less invasive treatments for what was once a “one-treatment-fits-all” disease; and improvements in both quality of life and survival rates.
Learn more about our continuing investment in research and the exciting research that we are funding, because nothing would make us happier than ending breast cancer forever.